{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:36:38Z","timestamp":1787160998327,"version":"build-2736575974"},"reference-count":49,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4,22]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Aberrant alternative splicing is one of the hallmarks of cancer and is potentially based on upregulated expression-of-splicing factors in some types of cancer. Our previous study suggested that the splicing factor RBM39 is significantly upregulated in multiple myeloma (MM) and that its upregulation is positively associated with poor prognosis. Here, we further demonstrate that the survival and proliferation of MM cells rely on RBM39 and that RBM39 knockdown inhibits the malignant growth of MM. Indisulam, a \u201cmolecular glue\u201d that mediates the proteasomal degradation of RBM39, has potent suppressive effects on MM both in\u00a0vitro and in\u00a0vivo. Deletion of RBM39 results in extensively altered splicing, with mis-splicing of MEK5 verified to inhibit the malignant growth of MM. Full-length MEK5 plays a vital role in maintaining MM cell survival, whereas aberrant MEK5 isoforms with exon loss exhibit loss of function and a propensity for proteasomal degradation. Targeting RBM39 or MEK5 synergistically increases the cytotoxicity of bortezomib in MM cells via the inhibition of p65. Our study validates the specific mechanism of RBM39 in MM, providing an approach for broader targeting and optimized therapeutic strategies for MM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025015815","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T17:13:17Z","timestamp":1741281197000},"page":"1991-2005","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":4,"title":["Targeting the RBM39-MEK5 axis synergizes with bortezomib to inhibit the malignant growth of multiple myeloma"],"prefix":"10.1182","volume":"9","author":[{"given":"Jia","family":"Liu","sequence":"first","affiliation":[{"name":"1Shanghai Institute of Hematology, State Key Laboratory for Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zilu","family":"Zhang","sequence":"additional","affiliation":[{"name":"1Shanghai Institute of Hematology, State Key Laboratory for Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbin","family":"Xu","sequence":"additional","affiliation":[{"name":"2Department of General Practice, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyuan","family":"Jia","sequence":"additional","affiliation":[{"name":"1Shanghai Institute of Hematology, State Key Laboratory for Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Zeng","sequence":"additional","affiliation":[{"name":"1Shanghai Institute of Hematology, State Key Laboratory for Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengyu","family":"Wu","sequence":"additional","affiliation":[{"name":"1Shanghai Institute of Hematology, State Key Laboratory for Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze","family":"Fu","sequence":"additional","affiliation":[{"name":"1Shanghai Institute of Hematology, State Key Laboratory for Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoguang","family":"Xu","sequence":"additional","affiliation":[{"name":"1Shanghai Institute of Hematology, State Key Laboratory for Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenjing","family":"Ye","sequence":"additional","affiliation":[{"name":"2Department of General Practice, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Wu","sequence":"additional","affiliation":[{"name":"2Department of General Practice, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanzhang","family":"Xu","sequence":"additional","affiliation":[{"name":"3Department of Pathophysiology, Hongqiao International Institute of Medicine, Shanghai Tongren Hospital\/Faculty of Basic Medicine, Key Laboratory of Cell Differentiation and Apoptosis of the Chinese Ministry of Education, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3288-5205","authenticated-orcid":false,"given":"Hu","family":"Lei","sequence":"additional","affiliation":[{"name":"3Department of Pathophysiology, Hongqiao International Institute of Medicine, Shanghai Tongren Hospital\/Faculty of Basic Medicine, Key Laboratory of Cell Differentiation and Apoptosis of the Chinese Ministry of Education, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingli","family":"Wu","sequence":"additional","affiliation":[{"name":"3Department of Pathophysiology, Hongqiao International Institute of Medicine, Shanghai Tongren Hospital\/Faculty of Basic Medicine, Key Laboratory of Cell Differentiation and Apoptosis of the Chinese Ministry of Education, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6067-4088","authenticated-orcid":false,"given":"Hua","family":"Yan","sequence":"additional","affiliation":[{"name":"1Shanghai Institute of Hematology, State Key Laboratory for Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China"},{"name":"2Department of General Practice, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,4,22]]},"reference":[{"issue":"9686","key":"2025042211214100100_bib1","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/S0140-6736(09)60221-X","article-title":"Multiple myeloma","volume":"374","author":"Raab","year":"2009","journal-title":"Lancet"},{"issue":"5","key":"2025042211214100100_bib2","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: a review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"key":"2025042211214100100_bib3","doi-asserted-by":"crossref","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple myeloma","volume":"3","author":"Kumar","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"2025042211214100100_bib4","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.molcel.2019.09.017","article-title":"Alternative splicing regulatory networks: functions, mechanisms, and evolution","volume":"76","author":"Ule","year":"2019","journal-title":"Mol Cell"},{"issue":"2","key":"2025042211214100100_bib5","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ccell.2018.07.001","article-title":"Comprehensive analysis of alternative splicing across tumors from 8,705 patients","volume":"34","author":"Kahles","year":"2018","journal-title":"Cancer Cell"},{"issue":"9","key":"2025042211214100100_bib6","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/j.celrep.2017.08.012","article-title":"The functional impact of alternative splicing in cancer","volume":"20","author":"Climente-Gonz\u00e1lez","year":"2017","journal-title":"Cell Rep"},{"issue":"9","key":"2025042211214100100_bib7","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/nm.4165","article-title":"Therapeutic targeting of splicing in cancer","volume":"22","author":"Lee","year":"2016","journal-title":"Nat Med"},{"issue":"3","key":"2025042211214100100_bib8","doi-asserted-by":"crossref","first-page":"736","DOI":"10.3324\/haematol.2019.235424","article-title":"Differential RNA splicing as a potentially important driver mechanism in multiple myeloma","volume":"106","author":"Bauer","year":"2021","journal-title":"Haematologica"},{"issue":"9","key":"2025042211214100100_bib9","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1261\/rna.057919.116","article-title":"Splicing-factor alterations in cancers","volume":"22","author":"Anczuk\u00f3w","year":"2016","journal-title":"RNA"},{"issue":"1","key":"2025042211214100100_bib10","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.cell.2019.12.011","article-title":"SnapShot: splicing alterations in cancer","volume":"180","author":"Rahman","year":"2020","journal-title":"Cell"},{"issue":"2","key":"2025042211214100100_bib11","doi-asserted-by":"crossref","first-page":"e684","DOI":"10.1002\/ctm2.684","article-title":"Splicing factor arginine\/serine-rich 8 promotes multiple myeloma malignancy and bone lesion through alternative splicing of CACYBP and exosome-based cellular communication. [published correction appears in Clin Transl Med. 2023;13(5):e1282]","volume":"12","author":"Zhang","year":"2022","journal-title":"Clin Transl Med"},{"issue":"1","key":"2025042211214100100_bib12","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ccell.2017.05.011","article-title":"ILF2 is a regulator of RNA splicing and DNA damage response in 1q21-amplified multiple myeloma","volume":"32","author":"Marchesini","year":"2017","journal-title":"Cancer Cell"},{"issue":"1","key":"2025042211214100100_bib13","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13045-017-0392-4","article-title":"NEK2 promotes aerobic glycolysis in multiple myeloma through regulating splicing of pyruvate kinase","volume":"10","author":"Gu","year":"2017","journal-title":"J\u00a0Hematol Oncol"},{"issue":"1","key":"2025042211214100100_bib14","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1038\/s41467-020-15521-4","article-title":"Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma","volume":"11","author":"Huang","year":"2020","journal-title":"Nat Commun"},{"issue":"47","key":"2025042211214100100_bib15","doi-asserted-by":"crossref","first-page":"eabj5405","DOI":"10.1126\/sciadv.abj5405","article-title":"Targeting the spliceosome through RBM39 degradation results in exceptional responses in high-risk neuroblastoma models","volume":"7","author":"Singh","year":"2021","journal-title":"Sci Adv"},{"issue":"4","key":"2025042211214100100_bib16","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1080\/15384101.2020.1711579","article-title":"Development of CAPER peptides for the treatment of triple negative breast cancer","volume":"19","author":"Chilewski","year":"2020","journal-title":"Cell Cycle"},{"issue":"3","key":"2025042211214100100_bib17","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ccell.2019.01.010","article-title":"Targeting an RNA-binding protein network in acute myeloid leukemia","volume":"35","author":"Wang","year":"2019","journal-title":"Cancer Cell"},{"issue":"6336","key":"2025042211214100100_bib18","doi-asserted-by":"crossref","first-page":"eaal3755","DOI":"10.1126\/science.aal3755","article-title":"Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15. [published correction appears in Science. 2017;356(6340):eaan7977]","volume":"356","author":"Han","year":"2017","journal-title":"Science"},{"issue":"1","key":"2025042211214100100_bib19","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1038\/s41467-022-28907-3","article-title":"Indisulam targets RNA splicing and metabolism to serve as a therapeutic strategy for high-risk neuroblastoma","volume":"13","author":"Nijhuis","year":"2022","journal-title":"Nat Commun"},{"issue":"1","key":"2025042211214100100_bib20","doi-asserted-by":"crossref","first-page":"4288","DOI":"10.1038\/s41467-021-24498-7","article-title":"Targeting KRAS4A splicing through the RBM39\/DCAF15 pathway inhibits cancer stem cells","volume":"12","author":"Chen","year":"2021","journal-title":"Nat Commun"},{"issue":"23","key":"2025042211214100100_bib21","doi-asserted-by":"crossref","first-page":"5068","DOI":"10.1016\/j.cell.2023.09.011","article-title":"Arginine reprograms metabolism in liver cancer via RBM39","volume":"186","author":"Mossmann","year":"2023","journal-title":"Cell"},{"issue":"6","key":"2025042211214100100_bib22","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.3324\/haematol.2019.218289","article-title":"Hypoxia-induced long non-coding RNA DARS-AS1 regulates RBM39 stability to promote myeloma malignancy","volume":"105","author":"Tong","year":"2020","journal-title":"Haematologica"},{"issue":"3","key":"2025042211214100100_bib23","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.cell.2017.06.010","article-title":"Defining a cancer dependency map","volume":"170","author":"Tsherniak","year":"2017","journal-title":"Cell"},{"issue":"Pt 4","key":"2025042211214100100_bib24","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1107\/S2059798316001248","article-title":"UHM-ULM interactions in the RBM39-U2AF65 splicing-factor complex","volume":"72","author":"Stepanyuk","year":"2016","journal-title":"Acta Crystallogr D Struct Biol"},{"issue":"3","key":"2025042211214100100_bib25","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ccr.2012.08.007","article-title":"A\u00a0small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance","volume":"22","author":"Chauhan","year":"2012","journal-title":"Cancer Cell"},{"issue":"8","key":"2025042211214100100_bib26","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.3324\/haematol.2013.087809","article-title":"Transcriptome analysis reveals molecular profiles associated with evolving steps of monoclonal gammopathies","volume":"99","author":"L\u00f3pez-Corral","year":"2014","journal-title":"Haematologica"},{"issue":"7","key":"2025042211214100100_bib27","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/sj.leu.2404253","article-title":"Prognostic value of cyclin D2 mRNA expression in newly diagnosed multiple myeloma treated with high-dose chemotherapy and tandem autologous stem cell transplantations","volume":"20","author":"Hanamura","year":"2006","journal-title":"Leukemia"},{"issue":"7","key":"2025042211214100100_bib28","doi-asserted-by":"crossref","first-page":"e27633","DOI":"10.2196\/27633","article-title":"Web-based survival analysis tool tailored for medical research (KMplot): development and implementation","volume":"23","author":"L\u00e1nczky","year":"2021","journal-title":"J\u00a0Med Internet Res"},{"issue":"W1","key":"2025042211214100100_bib29","doi-asserted-by":"crossref","first-page":"W488","DOI":"10.1093\/nar\/gkaa216","article-title":"SynergyFinder 2.0: visual analytics of multi-drug combination synergies. [published correction appears in Nucleic Acids Res. 2022;50(12):7198]","volume":"48","author":"Ianevski","year":"2020","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"2025042211214100100_bib30","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41589-019-0411-6","article-title":"Structural basis of indisulam-mediated RBM39 recruitment to DCAF15 E3 ligase complex. [published correction appears Nat Chem Biol. 2020;16(3):361]","volume":"16","author":"Bussiere","year":"2020","journal-title":"Nat Chem Biol"},{"issue":"6","key":"2025042211214100100_bib31","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/j.celrep.2019.09.079","article-title":"Aryl sulfonamides degrade RBM39 and RBM23 by recruitment to CRL4-DCAF15","volume":"29","author":"Ting","year":"2019","journal-title":"Cell Rep"},{"issue":"8","key":"2025042211214100100_bib32","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.bbagrm.2016.06.007","article-title":"Global regulation of alternative RNA splicing by the SR-rich protein RBM39","volume":"1859","author":"Mai","year":"2016","journal-title":"Biochim Biophys Acta"},{"issue":"14","key":"2025042211214100100_bib33","doi-asserted-by":"crossref","first-page":"7594","DOI":"10.3390\/ijms22147594","article-title":"The MEK5\/ERK5 pathway in health and disease","volume":"22","author":"Paudel","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"11","key":"2025042211214100100_bib34","doi-asserted-by":"crossref","first-page":"4492","DOI":"10.1182\/blood-2004-08-2985","article-title":"Multifunctional role of Erk5 in multiple myeloma","volume":"105","author":"Carvajal-Vergara","year":"2005","journal-title":"Blood"},{"issue":"4","key":"2025042211214100100_bib35","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.molmed.2020.01.006","article-title":"Targeted avenues for cancer treatment: the MEK5-ERK5 signaling pathway","volume":"26","author":"Pereira","year":"2020","journal-title":"Trends Mol Med"},{"key":"2025042211214100100_bib36","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.blre.2018.11.003","article-title":"The impact of NF-kappaB signaling on pathogenesis and current treatment strategies in multiple myeloma","volume":"34","author":"Vr\u00e1bel","year":"2019","journal-title":"Blood Rev"},{"issue":"19","key":"2025042211214100100_bib37","doi-asserted-by":"crossref","first-page":"16639","DOI":"10.1074\/jbc.M200360200","article-title":"NF-kappa B as a therapeutic target in multiple myeloma","volume":"277","author":"Hideshima","year":"2002","journal-title":"J\u00a0Biol Chem"},{"issue":"12","key":"2025042211214100100_bib38","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1038\/s41388-020-1163-1","article-title":"Targeting MEK5 impairs nonhomologous end-joining repair and sensitizes prostate cancer to DNA damaging agents","volume":"39","author":"Broustas","year":"2020","journal-title":"Oncogene"},{"issue":"2","key":"2025042211214100100_bib39","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1002\/jcb.29350","article-title":"Pharmacological inhibition of the MEK5\/ERK5 and PI3K\/Akt signaling pathways synergistically reduces viability in triple-negative breast cancer","volume":"121","author":"Wright","year":"2020","journal-title":"J\u00a0Cell Biochem"},{"issue":"4","key":"2025042211214100100_bib40","doi-asserted-by":"crossref","first-page":"e1718","DOI":"10.1038\/cddis.2015.83","article-title":"Aberrant MEK5\/ERK5 signalling contributes to human colon cancer progression via NF-kappaB activation","volume":"6","author":"Sim\u00f5es","year":"2015","journal-title":"Cell Death Dis"},{"issue":"4","key":"2025042211214100100_bib41","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.stemcr.2018.08.016","article-title":"Targeting the extracellular signal-regulated kinase 5 pathway to suppress human chronic myeloid leukemia stem cells","volume":"11","author":"Tusa","year":"2018","journal-title":"Stem Cell Rep"},{"key":"2025042211214100100_bib42","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.canlet.2017.01.034","article-title":"Oncogenic signaling of MEK5-ERK5","volume":"392","author":"Hoang","year":"2017","journal-title":"Cancer Lett"},{"issue":"50","key":"2025042211214100100_bib43","doi-asserted-by":"crossref","first-page":"8301","DOI":"10.1038\/sj.onc.1208026","article-title":"Stat3 upregulates MEK5 expression in human breast cancer cells","volume":"23","author":"Song","year":"2004","journal-title":"Oncogene"},{"issue":"2","key":"2025042211214100100_bib44","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ydbio.2012.09.013","article-title":"REST and its downstream molecule Mek5 regulate survival of primordial germ cells","volume":"372","author":"Okamura","year":"2012","journal-title":"Dev Biol"},{"issue":"7","key":"2025042211214100100_bib45","doi-asserted-by":"crossref","first-page":"5093","DOI":"10.1074\/jbc.M003719200","article-title":"MEKK2 associates with the adapter protein Lad\/RIBP and regulates the MEK5-BMK1\/ERK5 pathway","volume":"276","author":"Sun","year":"2001","journal-title":"J\u00a0Biol Chem"},{"issue":"51","key":"2025042211214100100_bib46","doi-asserted-by":"crossref","first-page":"36035","DOI":"10.1074\/jbc.274.51.36035","article-title":"MEKK3 directly regulates MEK5 activity as part of the big mitogen-activated protein kinase 1 (BMK1) signaling pathway","volume":"274","author":"Chao","year":"1999","journal-title":"J\u00a0Biol Chem"},{"issue":"16","key":"2025042211214100100_bib47","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.15252\/embj.201487808","article-title":"Ubiquitin-dependent regulation of MEKK2\/3-MEK5-ERK5 signaling module by XIAP and cIAP1","volume":"33","author":"Takeda","year":"2014","journal-title":"EMBO J"},{"issue":"4","key":"2025042211214100100_bib48","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/acn3.395","article-title":"PMP22 exon 4 deletion causes ER retention of PMP22 and a gain-of-function allele in CMT1E","volume":"4","author":"Wang","year":"2017","journal-title":"Ann Clin Transl Neurol"},{"issue":"15","key":"2025042211214100100_bib49","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.1016\/j.cell.2021.05.038","article-title":"Pharmacologic modulation of RNA splicing enhances anti-tumor immunity","volume":"184","author":"Lu","year":"2021","journal-title":"Cell"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/8\/1991\/2370087\/blooda_adv-2025-015815-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/8\/1991\/2370087\/blooda_adv-2025-015815-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T11:21:56Z","timestamp":1745320916000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/8\/1991\/535911\/Targeting-the-RBM39-MEK5-axis-synergizes-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,22]]},"references-count":49,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,4,22]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025015815","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,22]]}}}